

Psikologlar ve Psikolojik Danışmanlar İçin

PSİKOFARMAKOLOJİYE GİRİŞ

Prof. Dr. Yener ÖZEN

Erzincan-2024



© Copyright 2024

Bu kitabın, basım, yayın ve satış hakları Akademisyen Kitabevi A.Ş.'ye aittir. Anılan kuruluşun izni alınmadan kitabın tümü ya da bölümleri mekanik, elektronik, fotokopi, manyetik kağıt ve/veya başka yöntemlerle çoğaltılamaz, basılamaz, dağıtılamaz. Tablo, şekil ve grafikler izin alınmadan, ticari amaçlı kullanılamaz. Bu kitap T.C. Kültür Bakanlığı bandrolü ile satılmaktadır.

ISBN 978-625-399-792-2	Sayfa ve Kapak Tasarımı Akademisyen Dizgi Ünitesi
Kitap Adı Psikologlar ve Psikolojik Danışmanlar için Psikofarmakolojiye Giriş	Yayıncı Sertifika No 47518
Yazar Yener ÖZEN ORCID iD: 0000-0003-1147-0246	Baskı ve Cilt Vadi Matbaacılık
Yayın Koordinatörü Yasin DİLMEN	Bisac Code PSY020000
	DOI 10.37609/akya.3078

Kütüphane Kimlik Kartı

Özen, Yener.

Psikologlar ve Psikolojik Danışmanlar için Psikofarmakolojiye Giriş / Yener Özen.
Ankara : Akademisyen Yayınevi Kitabevi, 2024.

130 s. : 135x210 mm.

Kaynakça var.

ISBN 9786253997922

1. Psikoloji.

GENEL DAĞITIM

Akademisyen Kitabevi A.Ş.

Halk Sokak 5 / A

Yenişehir / Ankara

Tel: 0312 431 16 33

siparis@akademisyen.com

www.akademisyen.com

İÇİNDEKİLER

1. Psikofarmakolojiye Giriş	1
Psikofarmakolojinin Temelleri	3
Psikofarmakoloji ve Psikoterapi İlişkisi.....	7
Avantajlar:	7
Zorluklar:	8
Psikofarmakolojik İlaçların Tarihçesi	12
2. Psikofarmakolojiye Genel Bakış	18
Temel Nörobiyoloji ve Nörotransmitterler	23
İlaçların Beyin Üzerindeki Etki Mekanizmaları	26
Psikofarmakolojik İlaçların Sınıflandırılması	28
3. Antidepresanlar	29
Antidepresan İlaçların Sınıflandırılması ve Mekanizmaları.....	31
Antidepresanların Kullanım Alanları ve Etkileri.....	32
Antidepresanların Yan Etkileri ve İlaç Etkileşimleri	33
4. Anksiyolitikler ve Sedatif-Hipnotikler	35
Etki Mekanizmaları.....	36
Potansiyel Yan Etkiler:	44
Yönetim ve Önlemler	45
Genel Özellikler ve Kullanım Alanları	45
Benzodiazepinler ve Non-Benzodiazepinler	48
Etki Mekanizmaları.....	50
Kullanım Alanları.....	51
Potansiyel Yan Etkiler ve Güvenlik Profili	51
Yan Etkiler ve Bağımlılık Potansiyeli	51
Risk Yönetimi ve Önleme Stratejileri	53

5. Antipsikotikler.....	54
Birinci ve İkinci Kuşak Antipsikotikler.....	57
Örnekler.....	57
Avantajlar.....	61
Dezavantajlar ve Yan Etkiler.....	61
Örnekler.....	61
Avantajlar.....	65
Dezavantajlar ve Yan Etkiler.....	65
Antipsikotiklerin Kullanım Alanları ve Etkileri.....	66
Yan Etkiler ve İzlenmesi Gerekenler.....	67
6. Duygu Durum Düzenleyicileri.....	70
Duygu Durum Düzenleyicilerin Etkileri ve Yan Etkileri.....	75
7. Dikkat Eksikliği Hiperaktivite Bozukluğu ve Diğer Davranışsal Bozukluklar İçin İlaçlar.....	77
İlaçların Etkileri ve Yan Etkileri: Stimülanların Yan Etkileri:...	78
Non-Stimülanların Yan Etkileri:.....	78
Tedavi Sürecinde Dikkat Edilmesi Gerekenler:.....	78
Stimülanlar ve Non-Stimülanlar.....	79
Yaygın Stimülan İlaçlar:.....	79
Yan Etkiler:.....	80
Yaygın Non-Stimülan İlaçlar:.....	80
Yan Etkiler:.....	80
Kullanım Alanları ve Etkileri.....	81
Diğer Davranışsal Bozukluklar İçin İlaçlar: Anksiyete Bozuklukları ve Obsesif-Kompulsif Bozukluk (OKB) İçin İlaçlar:.....	82
Davranışsal ve Duygu Durum Bozuklukları İçin İlaçlar:.....	82
Yan Etkiler ve İzlenmesi Gerekenler.....	82
8. Bağımlılık ve Bağımlılık Tedavisinde Kullanılan İlaçlar.....	84
Alkol ve Madde Bağımlılığında Kullanılan İlaçlar.....	85
Detoksifikasyon ve Bakım Tedavileri.....	86
Yöntemler ve İlaçlar:.....	87
İlaç Kullanımı:.....	87

Yan Etkiler ve Tedavi Yaklaşımları.....	88
Yönetimi Zorlayan Yan Etkiler ve İlgili Tedavi Yaklaşımları....	88
9. Psikofarmakolojik İlaçların Psikoterapiye Etkisi	89
İlaç Kullanımının Terapötik İlişkiye Etkisi	90
Terapötik İlişki ve İlaç Tedavisine Uyum.....	91
Psikoterapi ve İlaç Tedavisinin Entegrasyonu	92
Hasta Yönetimi ve İlaç Uyumu.....	93
İlaç Uyumunu Artırmak İçin Stratejiler:	94
10. Psikofarmakoloji'de Etik ve Hukuki Konular	94
İlaç Reçetelendirme Yetkisi ve Sınırları.....	96
Hasta Bilgilendirme ve Onam	97
Mesleki Sorumluluk ve Etik İlkeler.....	98
Etik İlkeler:.....	98
11. İlaçlar Ve Psikoterapi Pratiğinde Karşılaşılan Sorunlar.....	99
Sık Görülen Yan Etkiler ve Yönetimi	100
Genel Öneriler:.....	101
İlaç Değişiklikleri ve Kesilme Sendromları	102
İlaç Etkileşimlerine Dikkat Etme	103
Önemli Psikofarmakolojik İlaç Etkileşimleri:	104
İlaç Etkileşimlerini Yönetme Stratejileri:	104
12. Sonuç.....	105
Psikofarmakolojik İlaçların Kapsamının Anlaşılması.....	105
Psikofarmakoloji'de Psikolojik Danışmanların Rolü	106
Sürekli Eğitim ve Güncel Bilgilere Erişim.....	108
Sonsöz.....	109
Kaynaklar	111

KAYNAKLAR

- Aboujaoude, E., & Salame, W. (2016). Naltrexone: A Pan-Addiction Treatment? *CNS Drugs*, 30(8), 719-733.
- Agelopoulos, E. (2003). Mood stabilizers: anticonvulsants. *Annals of General Hospital Psychiatry*, 2(1), S8.
- Akhondzadeh, S., & Maleki, J. (2007). Herbal Medicines In The Treatment of Psychiatric and Neurological Disorders. *Iranian Journal of Psychiatry*, 1, 1-11.
- Aleksandrova, L., & Phillips, A. (2021). Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics. *Trends in Pharmacological Sciences*,
- American Psychiatric Association. (2013). *Diagnostic and statistical manual of mental disorders* (5th ed.). Arlington, VA: American Psychiatric Publishing.
- Ansari, A., & Osser, D. (2020). *Psychopharmacology: A concise overview*, 3rd edition.
- Arnaout, B., & Petrakis, I. L. (2011). Sedative-hypnotics and anxiolytics. *Addiction Medicine: Science and Practice*, 511-523.
- Arnsten, A. F. T. (2006). Stimulants: Therapeutic actions in ADHD. *Neuropsychopharmacology*, 31(11), 2376-2383.
- Asnis, G., & Henderson, M. A. (2015). Levomilnacipran for the treatment of major depressive disorder: a review. *Neuropsychiatric Disease and Treatment*, 11, 125-135.
- Austin, J., Semaka, A., & Hadjipavlou, G. (2014). Conceptualizing genetic counseling as psychotherapy in the era of genomic medicine. *Journal of Genetic Counseling*, 23(6), 903-909.
- BalajiDeekshitulu, P. (2020). Herbal treatment in Mental health.
- Balogh, L., Tanaka, M., Török, N., Vécsei, L., & Taguchi, S. (2021). Crosstalk between existential phenomenological psychotherapy and neurological sciences in mood and anxiety disorders. *Biomedicine*, 9(4), 340.
- Ban, T. A. (2006). The role of serendipity in drug discovery. *Dialogue in Clinical Neuroscience*, 8(3), 335-344.
- Bandelow, B., Michaelis, S., & Wedekind, D. (2017). Treatment of anxiety disorders. *Dialogues in Clinical Neuroscience*, 19(2), 93-107.
- Bandelow, B., Sher, L., Bunevicius, R., Hollander, E., Kasper, S., Zohar, J., ... & Rihmer, Z. (2015). Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder, and posttraumatic stress disorder in primary care. *International Journal of Psychiatry in Clinical Practice*, 19(2), 77-84.
- Bandelow, B., Zohar, J., Hollander, E., Kasper, S., & Möller, H. J. (2008). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders. *World Journal of Biological Psychiatry*, 9(4), 248-312.
- Barsaglini, A., Sartori, G., Benetti, S., Pettersson-Yeo, W., & Mechelli, A. (2014).

- The effects of psychotherapy on brain function: A systematic and critical review. *Progress in Neurobiology*, 114, 1-14.
- Bateson, A. N. (2002). Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal. *Current Pharmaceutical Design*, 8(1), 5-21.
- Behars, J. O., & Gutheil, T. G. (2001). Informed consent in psychotherapy. *The American Journal of Psychiatry*, 158(1), 4-10.
- Beitman, B. D. (1991). Integrating Pharmacotherapy and Psychotherapy.
- Bellinghen, M. van, & Troch, C. (2001). Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial. *Journal of Child and Adolescent Psychopharmacology*, 11, 5-13.
- Berger, W., Mendlowicz, M. V., Marques-Portella, C., Kinrys, G., Fontenelle, L. F., Marmar, C. R., & Figueira, I. (2009). Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: A systematic review. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 33(2), 169-180.
- Blackwell, B., & Schmidt, G. L. (1984). Drug interactions in psychopharmacology. *The Psychiatric Clinics of North America*, 7(3), 625-637.
- Bourbeau, J., & Bartlett, S. J. (2008). Patient adherence in COPD. *Thorax*, 63, 831-838.
- Boyer, E. W., & Shannon, M. (2005). The serotonin syndrome. *New England Journal of Medicine*, 352(11), 1112-1120.
- Braslow, J., & Marder, S. (2019). History of psychopharmacology. *Annual Review of Clinical Psychology*, 15.
- Brodsky, H., & Andrews, G. (1983). Brief Psychotherapy in Family Practice. *British Journal of Psychiatry*, 143, 11-19.
- Brown, M. T., & Bussell, J. K. (2011). Medication adherence: WHO cares?. *Mayo Clinic Proceedings*, 86(4), 304-314.
- Brown, T. J., Smith, M. A., Jones, T. C., & Miller, B. D. (2022). *Modern Pharmacology With Clinical Applications*. Elsevier.
- Buchanan, R.W., Kreyenbuhl, J., Kelly, D.L., Noel, J.M., Boggs, D.L., Fischer, B.A., ... & Gellad, W.F. (2010). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. *Schizophrenia Bulletin*, 36(1), 71-93. <https://doi.org/10.1093/schbul/sbp116>
- Cahill, K., Stevens, S., Perera, R., & Lancaster, T. (2013). Pharmacological interventions for smoking cessation: an overview and network meta-analysis. *Cochrane Database of Systematic Reviews*, 2013(5).
- Callahan, A. M., Fava, M., & Rosenbaum, J. F. (1993). Drug interactions in psychopharmacology. *The Psychiatric Clinics of North America*, 16(3), 647-671.
- Campbell, M., & Cueva, J. E. (1995). Psychopharmacology in Child and Adolescent Psychiatry: A Review of the Past Five Years. *Journal of the American Academy of Child and Adolescent Psychiatry*, 34, 269-279.
- Chiu, C., Wang, Z., Hunsberger, J., & Chuang, D. (2013). Therapeutic Potential

- of Mood Stabilizers Lithium and Valproic Acid: Beyond Bipolar Disorder. *Pharmacological Reviews*, 65, 105-142
- Cipriani, A., Hawton, K., Stockton, S., & Geddes, J. R. (2013). Lithium in the prevention of suicide in mood disorders: Updated systematic review and meta-analysis. *BMJ*, 346, f3646.
- Clayton, A. H., Montejo, A. L., & Segraves, R. T. (2016). Major depressive disorder, antidepressants, and sexual dysfunction. *Journal of Clinical Psychiatry*, 77(3),.
- Connock, M., Juarez-Garcia, A., Jowett, S., Frew, E., Liu, Z., Taylor, R. J., ... & Taylor, R. S. (2007). Methadone and buprenorphine for the management of opioid dependence: A systematic review and economic evaluation. *Health Technology Assessment*, 11(9), 1-171.
- Correll, C. U. (2015). From receptor pharmacology to improved outcomes: Individualising the selection, dosing, and switching of antipsychotics. *European Psychiatry*, 30(Suppl 1), 1354-1366.
- Correll, C. U., Detraux, J., De Lepeleire, J., & De Hert, M. (2015). Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. *World Psychiatry*, 14(2), 119-136.
- Cottone, R. R., Tarvydas, V. M., & Hartley, M. T. (2016). Ethics and decision making in counseling and psychotherapy.
- Craighead, W. E., & Nemeroff, C. B. (2001). *The Corsini Encyclopedia of Psychology and Behavioral Science*. New York, NY: Wiley.
- Crowle, A. J., Douvas, G., & May, M. (1992). Chlorpromazine: a drug potentially useful for treating mycobacterial infections. *Chemotherapy*, 38(6), 410-419.
- Dalton, S. O., Johansen, C., Mellekjaer, L., Norgard, B., Sorensen, H. T., & Olsen, J. H. (2003). Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: A population-based cohort study. *Archives of Internal Medicine*, 163(1), 59-64.
- De Hert, M., Schreurs, V., Vancampfort, D., & VAN Winkel, R. (2009). Metabolic syndrome in people with schizophrenia: A review. *World Psychiatry*, 8(1), 15-22.
- Dev, V., & Raniwalla, J. (2000). Quetiapine: A review of its safety in the management of schizophrenia. *Drug Safety*, 23(4), 295-307.
- Domino, E. F. (1999). History of modern psychopharmacology: A personal view with an emphasis on antidepressants. *Psychosomatic Medicine*, 61(5), 591-598.
- Dubovsky, S. (2005). Who is teaching psychopharmacology? Who should be teaching psychopharmacology? *Academic Psychiatry*, 29(2), 155-161.
- Dyer, A. R., & Bloch, S. (1987). Informed consent and the psychiatric patient. *Journal of Medical Ethics*, 13(1), 12-16.
- Estrela, M., Herdeiro, M. T., Ferreira, P. L., & Roque, F. (2020). The use of antidepressants, anxiolytics, sedatives and hypnotics in Europe: focusing on

- mental health care in Portugal and prescribing in older patients. *International journal of environmental research and public health*, 17(22), 8612.
- Fallon, A. (2006). Informed Consent in the Practice of Group Psychotherapy. *International Journal of Group Psychotherapy*, 56(4), 431-45
- Faraone, S. V., & Buitelaar, J. (2010). Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. *European Child & Adolescent Psychiatry*, 19(4), 353-364.
- Fava, M., & Davidson, K. G. (1996). Definition and epidemiology of treatment-resistant depression. *Psychiatric Clinics of North America*, 19(2), 179-200.
- FDA. (2007). Antidepressant use in children, adolescents, and adults. Retrieved from <https://www.fda.gov/drugs/drug-safety-and-availability/antidepressant-use-children-adolescents-and-adults>
- Finn, C. T., & Smoller, J. W. (2006). Genetic counseling in psychiatry. *Harvard Review of Psychiatry*, 14(2), 109-121.
- Fitton, A., & Heel, R. (1990). Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia. *Drugs*, 40(5), 722-747.
- Fitzsimons, J., Berk, M., Lambert, T., Bourin, M., & Dodd, S. (2005). A review of clozapine safety. *Expert Opinion on Drug Safety*, 4(4), 731-744.
- Fulton, B., & Goa, K. (1997). Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. *Drugs*, 53(2), 281-298.
- Gabriel, M., & Sharma, V. (2017). Antidepressant discontinuation syndrome. *Canadian Medical Association Journal*, 189(E747).
- García, S., Martínez-Cengotitabengoa, M., López-Zurbano, S., Zorrilla, I., López, P., Vieta, E., & González-Pinto, A. (2016). Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: A systematic review. *Journal of Clinical Psychopharmacology*, 36(4), 355-371
- Geddes, J. R., & Miklowitz, D. J. (2013). Treatment of bipolar disorder. *Lancet*, 381(9878), 1672-1682.
- Gitlin, M. (2016). Lithium side effects and toxicity: prevalence and management strategies. *International Journal of Bipolar Disorders*, 4, 27.
- Glassman, A. H., & Shapiro, P. A. (1998). Depression and the course of coronary artery disease. *American Journal of Psychiatry*, 155(1), 4-11.
- Glossoff, H. L., Garcia, J. G., & Herlihy, B. (1999). Managed care: Ethical considerations for counselors. *Counseling and Values*, 44, 8-16.
- Grant, S., & Fitton, A. (1994). Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia. *Drugs*, 48(2), 253-273.
- Greenberg, M., Taylor, J., & Harris, R. (2020). The impact of benzodiazepines on cognition in the elderly population. *Journal of Clinical Psychiatry and Neuroscience*, 15(3), 154-162.
- Greenhill, L. L., Pliszka, S., Dulcan, M. K., Bernet, W., Arnold, V., Beitchman, J.,

- ... & Pruett, J. R. (2002). Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. *Journal of the American Academy of Child & Adolescent Psychiatry*, 41(2 Suppl), 26S-49S.
- Greenway, K. T., Garel, N., Jerome, L., & Feduccia, A. (2020). Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments. *Expert Review of Clinical Pharmacology*, 13(6), 655-670.
- Griffin III, C. E., Kaye, A. M., Bueno, F. R., & Kaye, A. D. (2013). Benzodiazepine pharmacology and central nervous system-mediated effects. *The Ochsner Journal*, 13(2), 214-223.
- Grinchii, D., & Dremencov, E. (2020). Mechanism of Action of Atypical Antipsychotic Drugs in Mood Disorders. *International Journal of Molecular Sciences*, 21
- Grunze, H. (2010). Anticonvulsants in bipolar disorder. *Journal of Mental Health*, 19(2), 127-141.
- Gutheil, T. (2012). Reflections on ethical issues in psychopharmacology: An American perspective. *International Journal of Law and Psychiatry*, 35(5-6), 387-391.
- Haddad, P. (2001). Antidepressant discontinuation syndromes. *Drug Safety*, 24, 183-197.
- Haddad, P., & Sharma, S. (2007). Adverse effects of atypical antipsychotics. *CNS Drugs*, 21(11), 911-936.
- Harris, R., & Jones, P. D. (2021). Benzodiazepine use in the elderly: Risk of falls and cognitive impairment. *Geriatric Medicine*, 37(2), 89-95.
- Healy, D. (1997). *The antidepressant era*. Harvard University Press.
- Hendin, H., Haas, A., Maltsberger, J., Koestner, B., & Szanto, K. (2006). Problems in psychotherapy with suicidal patients. *The American Journal of Psychiatry*, 163, 67-72.
- Hillhouse, T. M., & Porter, J. H. (2015). A brief history of the development of antidepressant drugs: From monoamines to glutamate. *Experimental and Clinical Psychopharmacology*, 23(1), 1-21.
- Hirschfeld, R. M. A. (2000). History and evolution of the monoamine hypothesis of depression. *Journal of Clinical Psychiatry*, 61(Suppl 6), 4-6.
- Ho, P. M., Bryson, C. L., & Rumsfeld, J. S. (2009). Medication Adherence: Its Importance in Cardiovascular Outcomes. *Circulation*, 119, 3028-3035.
- Hollon, S. D., Thase, M. E., & Markowitz, J. C. (2002). Treatment and prevention of depression. *Psychological Science in the Public Interest*, 3(2), 39-77.
- Hollon, S.D., DeRubeis, R.J., Fawcett, J., Amsterdam, J.D., Shelton, R.C., Zajecka, J., ... & Gallop, R. (2014). Effectiveness of cognitive-behavioral therapy with and without medication in the treatment of adult depression. *American Journal of Psychiatry*, 171(11), 1161-1173.
- Holt, J. P., & Wright, E. (1960). Preliminary results with fluphenazine (prolixin) in chronic psychotic patients. *The American Journal of Psychiatry*, 117(2),

157-159.

- Howes, O. D., & Kapur, S. (2009). The dopamine hypothesis of schizophrenia: version III—the final common pathway. *Schizophrenia Bulletin*, 35(3), 549-562.
- Howes, O. D., & Kapur, S. (2009). The dopamine hypothesis of schizophrenia: Version III—The final common pathway. *Schizophrenia Bulletin*, 35(3), 549-562.
- Howland, R. H. (2015). Bupirone: Back to the future. *Journal of Psychosocial Nursing and Mental Health Services*, 53(11), 21-24.
- Hughes, J. R., Stead, L. F., Hartmann-Boyce, J., Cahill, K., & Lancaster, T. (2007). Antidepressants for smoking cessation. *Cochrane Database of Systematic Reviews*, 2007(1).
- Hyman, S. E., & Nestler, E. J. (1996). Initiation and adaptation: A paradigm for understanding psychotropic drug action. *American Journal of Psychiatry*, 153(2), 151-162.
- Ingersoll, R. E. (2000). Teaching a psychopharmacology course to counselors: Justification, structure, and methods. *Counselor Education and Supervision*, 40(1), 58-69.
- Jensen, N. H., Rodriguiz, R., Caron, M., Wetsel, W., Rothman, R., & Roth, B. (2008). N-Desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT_{1A} agonist, as a putative mediator of quetiapine's antidepressant activity. *Neuropsychopharmacology*, 33(11), 2303-2312
- Johnson, L. M., & Smith, A. B. (2022). Overview of benzodiazepines in clinical practice. *Pharmacotherapy Journal*, 42(1), 56-68.
- Jonas, D. E., Amick, H. R., Feltner, C., Bobashev, G., Thomas, K., Wines, R., ... & Garbutt, J. C. (2014). Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. *JAMA*, 311(18), 1889-1900.
- Jones, T. C., Smith, M. A., & Brown, T. J. (2020). The use of sedative-hypnotic drugs in the treatment of insomnia: Risks and benefits. *Journal of Sleep Medicine and Disorders*, 6(1), 112-119.
- Kandel, E. R., Schwartz, J. H., & Jessell, T. M. (2000). *Principles of Neural Science* (4th ed.). McGraw-Hill.
- Kapczinski, F., Vieta, E., Andreazza, A. C., Frey, B. N., Gomes, F. A., Tramon-tina, J., ... & Post, R. M. (2009). Allostatic load in bipolar disorder: Implications for pathophysiology and treatment. *Neuroscience & Biobehavioral Reviews*, 33(4), 699-709.
- Kapur, S., & Mamo, D. (2003). Half a century of antipsychotics and still a central role for dopamine D₂ receptors. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 27(7), 1081-1090.
- Kasper, S., & Montgomery, S. A. (Eds.). (2013). *Handbook of Psychiatric Drugs*. Wiley-Blackwell.
- Katzung, B. G. (2017). *Basic and Clinical Pharmacology* (14th ed.). McGraw-Hill

- Education.
- Kim, H., Yumkham, S., Choi, J., Kim, E.-K., Kim, Y. S., Ryu, S., & Suh, P. (2006). Haloperidol induces calcium ion influx via L-type calcium channels in hippocampal HN33 cells and renders the neurons more susceptible to oxidative stress. *Molecules and Cells*, 22(1), 51-57.
- King, J. H., & Anderson, S. M. (2004). Therapeutic implications of pharmacotherapy: Current trends and ethical issues. *Journal of Counseling and Development*, 82, 329-336.
- Kirkham, J., Choi, N., & Seitz, D. (2016). Meta-analysis of problem solving therapy for the treatment of major depressive disorder in older adults. *International Journal of Geriatric Psychiatry*, 31, 526-535.
- Kollins, S. H., Jain, R., & Brams, M. (2011). Exploring the efficacy of medication in treating attention-deficit/hyperactivity disorder: A meta-analysis. *Postgraduate Medicine*, 123(5), 70-81.
- Konstantinidou, H., & Evans, C. (2015). Pharmacotherapy and psychotherapy: the challenges of integrating two paradigms. *Psychoanalytic Psychotherapy*, 29, 343-362.
- Kratochvil, C. J., Heiligenstein, J. H., Dittmann, R., Spencer, T. J., Biederman, J., Wernicke, J., ... & Michelson, D. (2003). Atomoxetine and methylphenidate treatment in children with ADHD: A prospective, randomized, open-label trial. *Journal of the American Academy of Child & Adolescent Psychiatry*, 42(7), 776-784.
- Kripke, D. F. (2016). Mortality risk of hypnotics: Strengths and limits of evidence. *Drug Safety*, 39(2), 93-107.
- LaGrotta, C., & Thomas, A. (2020). Benzodiazepines and Other Sedatives, Hypnotics, and Anxiolytics. *Absolute Addiction Psychiatry Review: An Essential Board Exam Study Guide*, 139-151.
- Lau, C. G., & Zukin, R. S. (2007). NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. *Nature Reviews Neuroscience*, 8(6), 413-426.
- Lawson, G. (1994). Monitoring of serum haloperidol. *Mayo Clinic Proceedings*, 69(2), 189-190.
- Lee, J. D., Nunes, E. V., Novo, P., Bachrach, K., Bailey, G. L., Bhatt, S., ... & Rotrosen, J. (2018). Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X-BOT): a multicentre, open-label, randomised controlled trial. *The Lancet*, 391(10118), 309-318.
- Lehmann, H., & Ban, T. (1997). The History of the Psychopharmacology of Schizophrenia. *The Canadian Journal of Psychiatry*, 42, 152-162.
- Lehmann, H., & Ban, T. (1997). The History of the Psychopharmacology of Schizophrenia. *The Canadian Journal of Psychiatry*, 42, 152-162.
- Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., & Örey, D. (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A mul-

- multiple-treatments meta-analysis. *The Lancet*, 382(9896), 951-962.
- Levant, R., & Shapiro, A. (2002). Training psychologists in clinical psychopharmacology. *Journal of Clinical Psychology*, 58(6), 611-615
- Li, H., Zhang, Y., Zhou, L., Han, F., Wang, M., Xue, M., & Qi, Z. (2014). Chlorpromazine confers neuroprotection against brain ischemia by activating BKCa channel. *European journal of pharmacology*, 735, 38-43.
- Linden, M., & Schermuly-Haupt, M. (2014). Definition, assessment and rate of psychotherapy side effects. *World Psychiatry*.
- Lu, L., Liu, Y., Zhu, W., Shi, J., Liu, Y., Ling, W., & Kosten, T. (2009). Traditional Medicine in the Treatment of Drug Addiction. *The American Journal of Drug and Alcohol Abuse*, 35(1), 1-11.
- MacLaughlin, E., Raehl, C., Treadway, A. K., Sterling, T. L., Zoller, D. P., & Bond, C. A. (2005). Assessing Medication Adherence in the Elderly. *Drugs & Aging*, 22, 231-255.
- Malenka, R. C., & Bear, M. F. (2004). LTP and LTD: An embarrassment of riches. *Neuron*, 44(1), 5-21.
- Malhi, G. S., & Outhred, T. (2016). Therapeutic mechanisms of lithium in bipolar disorder: Recent advances and current understanding. *CNS Drugs*, 30(10), 931-949.
- Mann, K., Leher, P., & Morgan, M. Y. (2013). The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. *Alcoholism: Clinical and Experimental Research*, 37(4), 540-550.
- Mantell, E., Ortiz, S. O., & Planthara, P. M. (2004). What price prescribing? A commentary on the effect of prescription authority on psychological practice. *Professional Psychology: Research and Practice*, 35(2), 164-169.
- Marrero, R. J., Fumero, A., de Miguel, A., & Peñate, W. (2020). Psychological factors involved in psychopharmacological medication adherence in mental health patients: A systematic review. *Patient Education and Counseling*.
- Matar, H., & Almerie, M. Q. (2013). Fluphenazine (oral) versus placebo for schizophrenia. *Schizophrenia Bulletin*, 39(6), 1187-1188.
- Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. *Cochrane Database of Systematic Reviews*, 2014(2).
- McHenry, L. (2006). Ethical issues in psychopharmacology. *Journal of Medical Ethics*, 32, 405-410.
- McHugh, R. K., Whitton, S. W., Peckham, A. D., Welge, J. A., & Otto, M. W. (2013). Patient preference for psychological vs pharmacologic treatment of psychiatric disorders: a meta-analytic review. *The Journal of Clinical Psychiatry*, 74, 595-602.
- McNicol, E., Horowicz-Mehler, N., Fisk, R., Bennett, K., Gialeli-Goudas, M., Chew, P., ... & Carr, D. (2003). Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. *The journal of*

- pain : official journal of the American Pain Society, 4(5), 231-256.
- Meltzer, H. (2013). Update on typical and atypical antipsychotic drugs. *Annual Review of Medicine*, 64, 393-406.
- Michelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, F. R., & Spencer, T. (2003). Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response study. *Pediatrics*, 112(5), e359.
- Miklowitz, D.J., & Scott, J. (2016). Psychosocial treatments for bipolar disorder: Cost-effectiveness, mediating mechanisms, and future directions. *Bipolar Disorders*, 18(3), 1-14. <https://doi.org/10.1111/bdi.12389>
- Miller, B. D., Brown, T. J., & Jones, T. C. (2019). Respiratory depression associated with sedative use: Evaluation and management in the emergency department. *Emergency Medicine Journal*, 36(8), 508-513.
- Miller, K. D., Greenberg, M., & Taylor, J. (2019). Mechanisms of action of benzodiazepines and therapeutic implications. *Neuropharmacology Reviews*, 24(4), 457-470.
- Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W., & Lieberman, J. A. (2012). Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. *Molecular Psychiatry*, 17(12), 1206-1227.
- Moskowitz, D. S., & Young, S. N. (2006). Ecological momentary assessment: What it is and why it is a method of the future in clinical psychopharmacology. *Journal of Psychiatry & Neuroscience*, 31(1), 13-20.
- Möhler, H. (2012). The GABA system in anxiety and depression and its therapeutic potential. *Neuropharmacology*, 62(1), 42-53.
- Muench, J., & Hamer, A. M. (2010). Adverse effects of antipsychotic medications. *American Family Physician*, 81(5), 617-622.
- Muijen, M., & Silverstone, T. (1987). A Comparative Hospital Survey of Psychotropic Drug Prescribing. *British Journal of Psychiatry*, 150, 501-504.
- Murray, C., & Murray, T. (2007). The family pharm: An ethical consideration of psychopharmacology in couple and family counseling. *The Family Journal*, 15, 65-71.
- Murru, A., Popovic, D., Pacchiarotti, I., Hidalgo, D., León-Caballero, J., Vieta, E. (2015). Management of Adverse Effects of Mood Stabilizers. *Current Psychiatry Reports*, 17(8), 1-10.
- Müller-Oerlinghausen, B. (1978). Ethical problems in clinical psychopharmacology. *International Journal of Clinical Pharmacology and Biopharmacy*, 16(10), 443-450.
- Myrick, H., & Anton, R. F. (1998). Treatment of alcohol withdrawal. *Alcohol Health and Research World*, 22(1), 38-43.
- Naranjo, C., Shulman, R., & Özdemir, V. (1997). Development and evaluation of a clinical psychopharmacology educational curriculum. *The Journal of Clinical Pharmacology*, 37.

- National Institute of Mental Health. (2016). Mental Health Medications. Retrieved from <https://www.nimh.nih.gov/health/topics/mental-health-medications/index.shtml>
- Nestler, E. J., Hyman, S. E., Malenka, R. C., & Holtzman, D. M. (2009). *Molecular neuropharmacology: A foundation for clinical neuroscience* (2nd ed.). McGraw-Hill Medical.
- Nestler, E. J., Hyman, S. E., Malenka, R. C., & Holtzman, D. M. (2009). *Molecular Neuropharmacology: A Foundation for Clinical Neuroscience* (2nd ed.). McGraw-Hill Medical.
- NIMH. (2016). Mental Health Medications. National Institute of Mental Health. <https://www.nimh.nih.gov/health/topics/mental-health-medications/index.shtml>
- O'Brien, C. P. (2005). Benzodiazepine use, abuse, and dependence. *Journal of Clinical Psychiatry*, 66(Suppl 2), 28-33.
- Osterberg, L., & Blaschke, T. (2005). Adherence to medication. *The New England Journal of Medicine*, 353(5), 487-497.
- Pittenger, C., Kelmendi, B., Bloch, M., Krystal, J. H., & Coric, V. (2005). Clinical treatment of obsessive compulsive disorder. *Psychiatry (Edgmont)*, 2(11), 34-43.
- Plank, L. (2011). Governmental oversight of prescribing medications: history of the US Food and Drug Administration and prescriptive authority. *Journal of Midwifery & Women's Health*, 56(3), 198-204.
- Pliszka, S. (2007). Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. *Journal of the American Academy of Child & Adolescent Psychiatry*, 46(7), 894-921.
- Pomerantz, A. M. (2015). Informed Consent, Psychotherapy.
- Purves, D., Augustine, G. J., Fitzpatrick, D., Hall, W. C., LaMantia, A. S., Mooney, R. D., & White, L. E. (2018). *Neuroscience* (6th ed.). Sinauer Associates.
- Raj, Y. (2004). Psychopharmacology of borderline personality disorder. *Current Psychiatry Reports*, 6, 225-231.
- Rang, H. P., Dale, M. M., Ritter, J. M., & Flower, R. J. (2015). *Rang & Dale's pharmacology* (8th ed.). Elsevier Health Sciences.
- Resnik, D. B., Ranelli, P. L., Og, B., & Rodriguez-Paez, A. C. (2000). The conflict between ethics and business in community pharmacy: What about patient counseling?. *Journal of Business Ethics*, 28, 179-186.
- Ressler, K. J., & Nemeroff, C. B. (2000). Role of norepinephrine in the pathophysiology and treatment of mood disorders. *Biological Psychiatry*, 48(9), 825-838.
- Sadock, B. J., Sadock, V. A., & Ruiz, P. (2014). *Kaplan & Sadock's synopsis of psychiatry: Behavioral sciences/clinical psychiatry* (11th ed.). Wolters Kluwer.
- Sandson, N. B., Armstrong, S. C., & Cozza, K. L. (2005). An overview of psychotropic drug-drug interactions. *Psychosomatics*, 46(5), 464-494.
- Sanford, M., & Keating, G. (2012). Quetiapine: A review of its use in acute ma-

- nia and depression associated with bipolar disorder. *CNS Drugs*, 26(5), 435-460
- Schermuly-Haupt, M., Linden, M., & Rush, A. (2018). Unwanted Events and Side Effects in Cognitive Behavior Therapy. *Cognitive Therapy and Research*.
- Scott, C. G. (2000). Ethical issues in addiction counseling. *Rehabilitation Counseling Bulletin*, 43, 209-214.
- Serretti, A., & Mandelli, L. (2010). Antidepressants and body weight: A comprehensive review and meta-analysis. *Journal of Clinical Psychiatry*, 71(10), 1259-1272.
- Shelton, R. (2006). The nature of the discontinuation syndrome associated with antidepressant drugs. *The Journal of clinical psychiatry*, 67 Suppl 4, 3-7.
- Shorter, E. (1997). *A history of psychiatry: From the era of the asylum to the age of Prozac*. John Wiley & Sons.
- Shorter, E., & Kosten, T. R. (2011). Novel pharmacotherapeutic treatments for substance addiction. *Annual Review of Medicine*, 62, 299-312.
- Shulman, K. I., Herrmann, N., & Walker, S. E. (2013). Current place of monoamine oxidase inhibitors in the treatment of depression. *CNS Drugs*, 27(10), 789-797.
- Skinner, M. D., Lahmek, P., Pham, H., & Aubin, H. J. (2014). Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. *PloS one*, 9(2), e87366.
- Smith, M. A. (2021). Anxiety disorders and the role of anxiolytics in their treatment. *Journal of Psychiatric Research*, 55, 102-109.
- Sparks, J., Duncan, B., & Miller, S. D. (2007). Integrating Psychotherapy and Pharmacotherapy. *Journal of Family Psychotherapy*, 17, 108-183.
- Sprenger, D., & Josephson, A. (1998). Integration of pharmacotherapy and family therapy in the treatment of children and adolescents. *Journal of the American Academy of Child and Adolescent Psychiatry*, 37(8), 887-889.
- Sproule, B. A., Naranjo, C. A., Bremner, K. E., & Hassan, P. C. (1997). Selective Serotonin Reuptake Inhibitors and CNS Drug Interactions. *Clinical Pharmacokinetics*, 33(6), 454-471.
- Srinivasan, V., de Berardis, D., Shillcutt, S. D., & Brzezinski, A. (2012). Role of melatonin in mood disorders and the antidepressant effects of agomelatine. *Expert Opinion on Investigational Drugs*, 21(10), 1503-1522.
- Stahl, S. M. (2013). *Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications* (4th ed.). Cambridge University Press.
- Stahl, S. M. (2020). *Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications* (5th ed.). Cambridge University Press.
- Steele, T., & Brahmī, Z. (1988). Chlorpromazine inhibits human natural killer cell activity and antibody-dependent cell-mediated cytotoxicity. *Biochemical and biophysical research communications*, 155(2), 597-602.
- Stone, M. H. (2002). Healing the mind: A history of psychiatry from antiquity to

- the present. *Psychiatric Services*, 53(8), 1072.
- Stroup, T., & Gray, N. (2018). Management of common adverse effects of antipsychotic medications. *World Psychiatry*.
- Strous, R. (2011). Ethical considerations in clinical training, care and research in psychopharmacology. *The International Journal of Neuropsychopharmacology*, 14(3), 413-424.
- Su, Y., Ryder, J., Li, B., Wu, X., Fox, N., Solenberg, P., Brune, K., Paul, S., Zhou, Y., Liu, F., & Ni, B. (2004). Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing. *Biochemistry*, 43(22), 6899-908*.
- Swayze, V. (1995). Frontal leukotomy and related psychosurgical procedures in the era before antipsychotics (1935-1954): a historical overview. *The American Journal of Psychiatry*, 152(4), 505-515.
- Tarsy, D., & Baldessarini, R. J. (2006). The pathophysiological basis of tardive dyskinesia. *Biological Psychiatry*, 59(3), 202-208.
- Taylor, J. (2021). Benzodiazepines: Mechanisms of action and role in anxiety disorders. *Expert Review of Neurotherapeutics*, 21(5), 473-483.
- Thekdi, S. M., Trinidad, A., & Roth, A. J. (2014). Psychopharmacology in cancer. *Current Psychiatry Reports*, 17.
- Totura, C. M. W., Fields, S. A., & Karver, M. S. (2018). The role of the therapeutic relationship in psychopharmacological treatment outcomes: A meta-analytic review. *Psychiatric Services*, 69(1), 41-47.
- U.S. National Library of Medicine. (2020). Antidepressants. MedlinePlus. Retrieved from <https://medlineplus.gov/antidepressants.html>
- Vella-Brincat, J., & Macleod, A. (2004). Haloperidol in palliative care. *Palliative Medicine*, 18,
- Wager, S., & Zammit, G. (1995). Psychopharmacology in clinical practice.
- Wagner, J., & Wagner, M. L. (2000). Non-benzodiazepines for the treatment of insomnia. *Sleep Medicine Reviews*, 4(6), 551-581.
- Warner, C. H., Bobo, W., Warner, C. J., Reid, S., & Rachal, J. C. (2006). Antidepressant discontinuation syndrome. *American family physician*, 74(3), 449-456.
- Wigal, S. B., Gupta, S., Guinta, D., Swanson, J. M. (2006). Relating efficacy measures to clinical significance in controlled, clinical trials of stimulant medications for ADHD. *Journal of Attention Disorders*, 10(2), 160-165.
- Wilens, T. E., Spencer, T. J., & Biederman, J. (2002). A review of the pharmacotherapy of adults with attention-deficit/hyperactivity disorder. *Journal of Attention Disorders*, 5(4), 189-202.
- Wiskerke, J., Pattij, T., Schoffelmeer, A., & de Vries, T. J. (2008). The role of CB1 receptors in psychostimulant addiction. *Addiction Biology*, 13,
- Xu, H., Yang, H.-J., & Rose, G. (2012). Chronic haloperidol-induced spatial memory deficits accompany the upregulation of D(1) and D(2) receptors in the caudate putamen of C57BL/6 mouse. *Life Sciences*, 91(9-10), 322-328.

- Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., ... & Berk, M. (2018). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. *Bipolar Disorders*, 20(S2), 97-170.
- Yosselson-Superstine, S., Sternik, D., & Liebenzon, D. (1979). Prescribing patterns in psychiatric hospitals in Israel. *Acta Psychiatrica Scandinavica*, 60,
- Youdim, M. B. H., & Bakhle, Y. S. (2006). Monoamine oxidase: Isoforms and inhibitors in Parkinson's disease and depressive illness. *British Journal of Pharmacology*, 147(S1), S287-S296.
- Youssef, F. (1984). Adherence to therapy in psychiatric patients: An empirical investigation. *International Journal of Nursing Studies*, 21(1), 51-57.
- Zhang, A., Park, S., Sullivan, J. E., & Jing, S. (2018). The Effectiveness of Problem-Solving Therapy for Primary Care Patients' Depressive and/or Anxiety Disorders. *The Journal of the American Board of Family Medicine*, 31, 139-150.
- Zhang, Z.-J. (2004). Therapeutic effects of herbal extracts and constituents in animal models of psychiatric disorders. *Life sciences*, 75(14), 1659-1699.
- Zhou, X., Dong, X. W., & Priestley, T. (2006). The neuroleptic drug, fluphenazine, blocks neuronal voltage-gated sodium channels. *Brain Research*, 1106, 72-81.